Company Profile

SBI Biotech Co., Ltd. is a bio-venture firm envisaged and founded by SBI Holdings President & CEO, Mr. Yoshitaka Kitao and Molecular Biologist, Dr. Ken-ichi Arai.

SBI Biotech is

Venture that links latest achievement in life science to state-of-the-art treatment and innovative drug discovery.

Venture that can promote drug development from seed discovery to clinical studies.

Venture that identifies promising drug seeds and develops drug pipelines from the world.

Global venture wherein researchers from Japan, U.S., Israel, China, Korea and the other countries to cooperate across borders.

Company Fact Sheet

As of December 31, 2016

Company NameSBI Biotech Co., Ltd.
Capital
(As of April 29, 2017)
100,000 thousand Yen
Board of Directors
(As of March 21, 2017)
Director, Chairman
Ken-ichi Arai,MD,PhD
Representative Director, President
Takeshi Irie
Director
Eiji Esashi,PhD
Director
Koji Nakano
Director
Masahiro Kami,PhD
Director
Daniel Zurr,PhD
Board of Corporate Auditors
(As of March 21, 2017)
Standing Corporate Auditor
Ichiro Hamamoto
Corporate Auditor
Junji Maruko
Corporate Auditor
Tsunehiko Kuwata
Date of FoundationMarch 30,2001
Head OfficeIzumi Garden Tower 18F
1-6-1 Roppongi, Minato-ku Tokyo 106-6018Map
Telephone:+81-3-6229-0787  Fax:+81-3-3583-2022
Number of shares issued99,672
Employee18
Principal SubsidiariesQuark Pharmaceuticals, Inc.
6501Dumbarton Circle, Fremont,California, USA

Origin of Company Name

We named our company "SBI Biotech" to indicate our wishes, as the first bio-venture firm in the SBI Group, to contribute to society through commercializing various promising and innovative drug seeds.

sbi biotech logo image

 Back to top